https://www.selleckchem.com/pr....oducts/danirixin.htm
ognosis. The addition of targeted agents and immune checkpoint inhibitors in the perioperative setting appear to be promising although further research is required in this area to assess efficacy. Further clinical research is required to identify new agents and approaches to treatment to improve the survival of these patients. At present, regorafenib and fruquintinib are the standard regimens for refractory metastatic colorectal cancer patients in China, but both options have limited efficacy. The aim of this study was to investigate